10-Q: Denali Capital Acquisition Corp. Reports Net Income of $713,242 for First Half of 2024 Amidst Business Combination Efforts

Denali Capital Acquisition Corp. reported a net income of $713,242 for the first six months of 2024, while navigating the complexities of finding a suitable business combination target.

Summary

• Denali Capital Acquisition Corp., a blank check company, released its financial results for the quarter ended June 30, 2024.
• The company reported a net income of $448,912 for the three months ended June 30, 2024, and a net income of $713,242 for the six months ended June 30, 2024.
• These results are primarily due to income earned on investments held in the Trust Account, which amounted to $640,157 for the quarter and $1,294,042 for the six-month period.
• The company's formation and operating costs were $168,186 for the quarter and $536,438 for the six-month period.
• Interest expenses were $23,059 for the quarter and $44,362 for the six-month period.
• The company's cash and investments held in the Trust Account totaled $52,072,006 as of June 30, 2024.
• The company has been actively seeking a business combination, recently terminating a merger agreement with Longevity Biomedical, Inc. and entering into a letter of intent with Semnur Pharmaceuticals, Inc.
• The company extended the deadline to complete a business combination to April 11, 2025, with monthly extensions possible through additional deposits into the Trust Account.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the termination of the merger agreement, the significant redemptions, the working capital deficit, and the need for additional financing. However, the company is actively pursuing a new business combination and has extended its deadline, which provides some hope for the future.

Positives

• The company generated a net income of $713,242 for the first six months of 2024.
• The Trust Account balance remains substantial at $52,072,006.
• The company has secured an extension to complete a business combination until April 11, 2025.
• Denali has regained compliance with Nasdaq listing requirements.
• The company is actively pursuing a new business combination target after terminating the previous agreement.

Negatives

• The company incurred significant formation and operating costs of $536,438 for the first half of 2024.
• The merger agreement with Longevity Biomedical, Inc. was terminated.
• Shareholder redemptions resulted in a significant reduction of funds in the Trust Account.
• The company has a working capital deficit of $6,275,340 as of June 30, 2024.
• The company's cash outside of the Trust Account is minimal at $1,500.

Risks

• The company may not be able to complete a business combination within the extended timeframe.
• The company may require additional financing to complete a business combination.
• There is no guarantee that the letter of intent with Semnur will result in a definitive merger agreement.
• The company's working capital deficit raises concerns about its ability to operate without additional funding.
• The company's minimal cash outside of the Trust Account limits its operational flexibility.

Future Outlook

The company intends to use the funds in the Trust Account to complete a business combination and is actively seeking a new target after terminating the Longevity merger. The company has extended the deadline to complete a business combination to April 11, 2025, with monthly extensions possible through additional deposits into the Trust Account. The company is also exploring a potential business combination with Semnur Pharmaceuticals, Inc.

Management Comments

• Management believes that the company will not have sufficient working capital and borrowing capacity to meet its needs through the consummation of the initial Business Combination.
• Management intends to actively monitor the company's MVLS and may evaluate options to resolve the deficiency and regain compliance with the MVLS requirement.

Industry Context

The report reflects the challenges faced by SPACs in finding suitable merger targets and the impact of market conditions on their operations. The termination of the Longevity merger and the subsequent search for a new target are common occurrences in the SPAC landscape. The extension of the business combination deadline and the need for additional financing are also typical challenges faced by SPACs.

Comparison to Industry Standards

• The financial performance of Denali is typical for a SPAC in its pre-merger phase, with minimal operating revenue and reliance on interest income from the Trust Account.
• The company's operating expenses are in line with industry standards for SPACs during the search and due diligence phase.
• The redemptions of public shares are a common occurrence for SPACs, especially when the initial business combination is delayed or terminated.
• The extension of the business combination deadline is a common strategy used by SPACs to provide more time to find a suitable target.
• The company's cash position outside of the Trust Account is minimal, which is typical for SPACs that rely heavily on the Trust Account for funding.

Related Party Transactions

• The company has entered into several related-party transactions with its Sponsor, including loans and convertible promissory notes.
• The Sponsor has agreed to deposit funds into the Trust Account for monthly extensions of the business combination deadline.

Stakeholder Impact

• Shareholders have experienced significant redemptions, reducing the funds in the Trust Account.
• The company's employees and management are impacted by the uncertainty surrounding the business combination.
• The company's creditors are exposed to the risk of the company not completing a business combination.
• The company's potential target business is impacted by the uncertainty surrounding the business combination.

Next Steps

• The company will continue to seek a business combination target.
• The company will negotiate a definitive merger agreement with Semnur Pharmaceuticals, Inc.
• The company will continue to monitor its compliance with Nasdaq listing rules.
• The company will seek additional financing if needed to complete a business combination.
• The company will continue to extend the business combination deadline on a monthly basis if needed.

Key Dates

Keywords

business combination, SPAC, merger, acquisition, trust account, redemption, Nasdaq, financial results, promissory note, extension